Omnipod® 5 Automated Insulin Delivery System Now CE marked!

Omnipod® 5 Effective, automated insulin control

Omnipod® 5, the first tubeless, hybrid closed loop system integrated with Dexcom G6, is now CE marked for people with type 1 diabetes aged 2 years and older.

Omnipod 5 controller

Tubeless, Waterproof*, Wearable Pod

Integrated with Dexcom

Pod and Dexcom G6 shown without necessary adhesive.
The Dexcom G6 CGM requires a separate prescription and is necessary to use Omnipod 5 in Automated mode.

Improved Clinical Results3,4 with no more multiple daily injections, tubing or fingersticks**


time in range at a target of 110mg/dl (6.1mmol/L) in adults and adolescents (14-70 years) and 68%  overall TIR in children (2-13.9 years).


was significantly reduced in very young children (2.0-5.9 years), children (6-13.9 years) and adults and adolescents (14-70 years) by 0.5%, 0.7% and 0.4% respectively3,4.


reduced time in hyperglycaemia in children, and 24% in adults and adolescents.


reduction in hypoglycaemia overnight and 46% overall in adults and adolescents.

**Fingersticks required for diabetes treatment decisions if symptoms or expectations do not match CGM sensor readings.


The Omnipod® 5 System provides personalised and adaptive insulin delivery

Predictive, adaptive SmartAdjust™ algorithm built into the Pod.


Predicts glucose 60 minutes into the future.3


Adjusts insulin delivery proactively using the customisable glucose targets from 110 mg/dL to 150 mg/dL (6.1-8.3 mmol/L)3


Delivers insulin doses every 5 minutes (as needed) to help protect against hyperglycemia and hypoglycemia3

SmartBolus Calculator

Omnipod® 5 is the only system to incorporate CGM value AND trend into the SmartBolus Calculator.

  • Can increase or decrease suggested bolus, based on CGM value and trend
  • May reduce the suggested bolus, based on existing Insulin On Board (IOB)


The Activity Feature

  • Reduces automated insulin delivery and temporarily sets the Target Glucose to 150 mg/dL (8.3 mmol/L)
  • May be considered in times where glucose levels typically go low, such as exercise

Want to be kept updated on the latest on Omnipod 5?

Looking for more information about Omnipod® 5?

Check out the Omnipod 5 FAQS

Join our webinars and learn more with our educational hub

1. Dexcom G6 CGM System sold separately.

2. The Omnipod®5 System must be used with the Dexcom G6 app and is not compatible with the Dexcom G6 receiver. Dexcom compatible smart devices sold separately: compatibility

3. Brown S. et al. Multicenter trial of a tubeless, on-body automated insulin delivery system with customizable glycemic targets in pediatric and adult participants with type 1 diabetes. Diabetes Care. 2021;44(7):1630-1640. Prospective pivotal trial in 240 participants with T1D aged 6-70yrs [adults/adolescents (n=128; aged 14-70yrs0 children (n=112; aged 6-13.9 yrs)]. Study included a 14-day standard therapy (ST) phase followed by a 3-month Omnipod®5 hybrid closed-loop s(HCL) phase. Mean time in hyperglycemic range (>180 mg/dL) as measured by CGM in adults/adolescents and children ST vs. 3-mo Omnipod®5: 32.4% vs. 24.7%; 45.3% vs. 30.2%, P<0.0001, respectively. Median time in hypoglycemic range (<70 mg/dL) as measured by CGM in adults/adolescents and children ST vs. 3-mo Omnipod®5: 2.0% vs. 1.1%, P<0.0001; 1.4% vs. 1.5%, P=0.8153, respectively. Mean time in range (70-180 mg/dL) during 110 mg/dL Target BG in adults/adolescents (n=121) =75.6%. Mean time in range (70-180 mg/dL; 12AM to <6Am) in adults/adolescents and children as measured by CGM during St vs. 3-mo Omnipod®5: 64.3% vs. 78.1%; 55.3% vs. 78.1%, P<0.0001, respectively. Median time in hypoglycemic range in adults and adolescents (<70 mg/dL 12AM- <6AM) as measured by CGM: ST=2.07%, 3-mo Omnipod®5 =0.82%, P<0.0001. Comparison is a relative change. Mean time 70-180 mg/dL as measured by CGM in adults/adolescents and children, ST vs. 3-mo Omnipod®5: 64.7% vs. 73.9%; 52.5% vs. 68.0%, P<0.0001, respectively.

4. Sherr JL et al. Safety and glycemic outcomes with a tubeless automated insulin delivery system in very young children with type 1 diabetes: a single-arm, multicenter clinical trial. Diabetes Care. 2022; doi: 10.2337/dc21-2359 [Online ahead of print]. Prospective trial in 80 participants with T1D aged 2 - 5.9 yrs. Study included a 14-day standard therapy (ST) phase followed by a 3-month Omnipod 5 hybrid closed-loop (HCL) phase. Mean HbA1c: ST vs. Omnipod 5 use in very young children (2 - 5.9 yrs) 7.4% vs 6.9%, P<0.05.


Risk Statement
The Omnipod 5 Automated Insulin Delivery System is indicated for use by individuals with type 1 diabetes mellitus in persons 2 years of age and older. The Omnipod 5 System is intended for single patient, home use and requires supervision of the user's healthcare professional. The Omnipod 5 System is compatible with the following U-100 insulins: NovoRapid®, Humalog®, and Admelog®. 

The Omnipod 5 Pump (Pod) is intended for the subcutaneous delivery of insulin, at set and variable rates, for the management of diabetes mellitus in persons requiring insulin. The Omnipod 5 Pump is able to reliably and securely communicate with compatible, digitally connected devices, including automated insulin dosing software, to receive, execute, and confirm commands from these devices. SmartAdjust™ technology is intended for use with compatible integrated continuous glucose monitors (iCGM) to automatically increase, decrease, and pause delivery of insulin based on current and predicted glucose values. The  Omnipod 5 SmartBolus Calculator is intended to calculate a suggested bolus dose based on user-entered carbohydrates, most recent sensor glucose value (or blood glucose reading if using fingerstick), rate of change of the sensor glucose (if applicable), insulin on board (IOB), and programmable correction factor, insulin to carbohydrate ratio, and target glucose value. 

WARNING: SmartAdjust technology should NOT be used by anyone under the age of 2 years old. SmartAdjust technology should also NOT be used in people who require less than 5 units of insulin per day as the safety of the technology has not been evaluated in this population. 

The Omnipod 5 System is NOT recommended for people who are unable to monitor glucose as recommended by their healthcare provider, are unable to maintain contact with their healthcare provider, are unable to use the Omnipod 5 System according to instructions, are taking hydroxyurea as it could lead to falsely elevated CGM values and result in over-delivery of insulin that can lead to severe hypoglycemia, and do NOT have adequate hearing and/or vision to allow recognition of all functions of the Omnipod 5 System, including alerts, alarms, and reminders. Device components including the Pod, CGM transmitter, and CGM sensor must be removed before Magnetic Resonance Imaging (MRI), Computed Tomography (CT) scan, or diathermy treatment. In addition, the Controller and smartphone should be placed outside of the procedure room. Exposure to MRI, CT, or diathermy treatment can damage the components. Visit for additional important safety information.

WARNING: DO NOT start to use the Omnipod 5 System or change settings without adequate training and guidance from a healthcare provider. Initiating and adjusting settings incorrectly can result in over-delivery or under-delivery of insulin, which could lead to hypoglycemia or hyperglycemia.

Regional Disclaimer

Are you a resident of the United Kingdom?

Yes No

The content of the webpage that you are about to access is exclusively reserved for residents of the United Kingdom.

If you are a resident of the United Kingdom, please click 'Yes' to continue. If not, please click 'No' to exit and do not access the web pages. If you selected this country/language in error, you can go back to the previous page and select your country/language.

Thank you.

Please verify that you are a Healthcare Professional.

The content on this section of our website is intended for United Kingdom Healthcare Professionals only.

If you are not a United Kingdom Healthcare Professional, you will be redirected to the Omnipod® Homepage.

License number is required.